7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection
Lancet Infect Dis
.
2023 Feb;23(2):150-152.
doi: 10.1016/S1473-3099(22)00834-9.
Epub 2023 Jan 11.
Authors
Ulrika Marking
1
,
Oscar Bladh
1
,
Sebastian Havervall
1
,
Julia Svensson
2
,
Nina Greilert-Norin
1
,
Katherina Aguilera
1
,
Martha Kihlgren
1
,
Ann-Cristin Salomonsson
1
,
Maja Månsson
1
,
Radiosa Gallini
3
,
Cecilia Kriegholm
3
,
Philip Bacchus
4
,
Sophia Hober
5
,
Max Gordon
1
,
Kim Blom
6
,
Anna Smed-Sörensen
2
,
Mikael Åberg
3
,
Jonas Klingström
7
,
Charlotte Thålin
8
Affiliations
1
Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm, 18288, Sweden.
2
Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
3
Department of Medical Sciences, Clinical Chemistry and SciLifeLab, Uppsala University, Uppsala, Sweden.
4
Department of Laboratory Medicine, Lund University, Lund, Sweden.
5
Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden.
6
Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm, 18288, Sweden; Public Health Agency of Sweden, Solna, Sweden.
7
Public Health Agency of Sweden, Solna, Sweden; Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
8
Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm, 18288, Sweden. Electronic address:
[email protected]
.
PMID:
36640796
PMCID:
PMC9833832
DOI:
10.1016/S1473-3099(22)00834-9
No abstract available
Publication types
Letter
MeSH terms
Antibodies, Neutralizing
Antibodies, Viral
COVID-19*
Humans
Immunity, Mucosal
Immunoglobulin A*
SARS-CoV-2
Substances
Immunoglobulin A
Antibodies, Viral
Antibodies, Neutralizing